The Lions Health 2018 jury brought 10 senior communications executives together in Cannes, with representatives from China, Australia, UK, US, Brazil, Dubai, Ireland and Denmark.
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.